FDA in Drafting Phase for LDT Oversight

The agency's CDRH branch is currently weighing options on regulating lab-developed tests and is considering looking at 'high-risk' tests first.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.